Naturalendo Tech Swings to Profit in Separate Q1 2026; Consolidated Loss Continues
Separate operating profit of KRW 0.23 billion, turning from loss of KRW 2.81 billion in prior year
Consolidated operating loss of KRW 0.07 billion, but net profit attributable to parent of KRW 0.11 billion (vs. net loss of KRW 0.81 billion a year ago)
Consolidated revenue of KRW 5.7 billion, down 8.6% YoY from KRW 6.2 billion
R&D expenditure of KRW 0.61 billion, 10.69% of revenue
Subsidiary Endoderma's negative equity deepened to KRW -1.57 billion from -1.19 billion
Separate borrowings decreased to KRW 7.76 billion from KRW 8.35 billion at year-end 2025